APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients
Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial...
Saved in:
| Published in | Hepatology international Vol. 15; no. 4; pp. 833 - 851 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New Delhi
Springer India
01.08.2021
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1936-0533 1936-0541 1936-0541 |
| DOI | 10.1007/s12072-021-10223-5 |
Cover
| Abstract | Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial issues with pros and cons. Because seroclearance of hepatitis B surface (HBsAg) as functional cure is not easily achievable, a finite therapy including sequential 48-week pegylated interferon therapy may provide an opportunity to facilitate HBsAg seroclearance by the rejuvenation of exhausted immune cells. However, the cost of stopping NA is the high incidence of virological relapse and surge of alanine aminotransferase (ALT) levels, which may increase the risk of adverse outcomes (e.g., decompensation, fibrosis progression, HCC, or liver-related mortality). So far, the APASL criteria to stop NA treatment is undetectable HBV DNA levels with normalization of ALT; however, this criterion for cessation of treatment is associated with various incidence rates of virological/clinical relapse and more than 40% of NA-stoppers eventually receive retreatment. A very intensive follow-up strategy and identification of low-risk patients for virological/clinical relapse by different biomarkers are the keys to stop the NA treatment safely. Recent studies suggested that decreasing HBsAg level at the end-of-treatment to < 100–200 IU/mL seems to be a useful marker for deciding when to discontinue NAs therapy. In addition, several viral and host factors have been reviewed for their potential roles in predicting clinical relapse. Finally, the APASL guidance has proposed rules to stop NA and the subsequent follow-up strategy to achieve a better prognosis after stopping NA. In general, for both HBeAg-positive and HBeAg-negative patients who have stopped treatment, these measurements should be done every 1–3 months at the minimum until 12 months. |
|---|---|
| AbstractList | Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial issues with pros and cons. Because seroclearance of hepatitis B surface (HBsAg) as functional cure is not easily achievable, a finite therapy including sequential 48-week pegylated interferon therapy may provide an opportunity to facilitate HBsAg seroclearance by the rejuvenation of exhausted immune cells. However, the cost of stopping NA is the high incidence of virological relapse and surge of alanine aminotransferase (ALT) levels, which may increase the risk of adverse outcomes (e.g., decompensation, fibrosis progression, HCC, or liver-related mortality). So far, the APASL criteria to stop NA treatment is undetectable HBV DNA levels with normalization of ALT; however, this criterion for cessation of treatment is associated with various incidence rates of virological/clinical relapse and more than 40% of NA-stoppers eventually receive retreatment. A very intensive follow-up strategy and identification of low-risk patients for virological/clinical relapse by different biomarkers are the keys to stop the NA treatment safely. Recent studies suggested that decreasing HBsAg level at the end-of-treatment to < 100-200 IU/mL seems to be a useful marker for deciding when to discontinue NAs therapy. In addition, several viral and host factors have been reviewed for their potential roles in predicting clinical relapse. Finally, the APASL guidance has proposed rules to stop NA and the subsequent follow-up strategy to achieve a better prognosis after stopping NA. In general, for both HBeAg-positive and HBeAg-negative patients who have stopped treatment, these measurements should be done every 1-3 months at the minimum until 12 months.Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial issues with pros and cons. Because seroclearance of hepatitis B surface (HBsAg) as functional cure is not easily achievable, a finite therapy including sequential 48-week pegylated interferon therapy may provide an opportunity to facilitate HBsAg seroclearance by the rejuvenation of exhausted immune cells. However, the cost of stopping NA is the high incidence of virological relapse and surge of alanine aminotransferase (ALT) levels, which may increase the risk of adverse outcomes (e.g., decompensation, fibrosis progression, HCC, or liver-related mortality). So far, the APASL criteria to stop NA treatment is undetectable HBV DNA levels with normalization of ALT; however, this criterion for cessation of treatment is associated with various incidence rates of virological/clinical relapse and more than 40% of NA-stoppers eventually receive retreatment. A very intensive follow-up strategy and identification of low-risk patients for virological/clinical relapse by different biomarkers are the keys to stop the NA treatment safely. Recent studies suggested that decreasing HBsAg level at the end-of-treatment to < 100-200 IU/mL seems to be a useful marker for deciding when to discontinue NAs therapy. In addition, several viral and host factors have been reviewed for their potential roles in predicting clinical relapse. Finally, the APASL guidance has proposed rules to stop NA and the subsequent follow-up strategy to achieve a better prognosis after stopping NA. In general, for both HBeAg-positive and HBeAg-negative patients who have stopped treatment, these measurements should be done every 1-3 months at the minimum until 12 months. Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial issues with pros and cons. Because seroclearance of hepatitis B surface (HBsAg) as functional cure is not easily achievable, a finite therapy including sequential 48-week pegylated interferon therapy may provide an opportunity to facilitate HBsAg seroclearance by the rejuvenation of exhausted immune cells. However, the cost of stopping NA is the high incidence of virological relapse and surge of alanine aminotransferase (ALT) levels, which may increase the risk of adverse outcomes (e.g., decompensation, fibrosis progression, HCC, or liver-related mortality). So far, the APASL criteria to stop NA treatment is undetectable HBV DNA levels with normalization of ALT; however, this criterion for cessation of treatment is associated with various incidence rates of virological/clinical relapse and more than 40% of NA-stoppers eventually receive retreatment. A very intensive follow-up strategy and identification of low-risk patients for virological/clinical relapse by different biomarkers are the keys to stop the NA treatment safely. Recent studies suggested that decreasing HBsAg level at the end-of-treatment to < 100–200 IU/mL seems to be a useful marker for deciding when to discontinue NAs therapy. In addition, several viral and host factors have been reviewed for their potential roles in predicting clinical relapse. Finally, the APASL guidance has proposed rules to stop NA and the subsequent follow-up strategy to achieve a better prognosis after stopping NA. In general, for both HBeAg-positive and HBeAg-negative patients who have stopped treatment, these measurements should be done every 1–3 months at the minimum until 12 months. Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) and cirrhosis-related complications through profound viral suppression. However, indefinite therapy raises several crucial issues with pros and cons. Because seroclearance of hepatitis B surface (HBsAg) as functional cure is not easily achievable, a finite therapy including sequential 48-week pegylated interferon therapy may provide an opportunity to facilitate HBsAg seroclearance by the rejuvenation of exhausted immune cells. However, the cost of stopping NA is the high incidence of virological relapse and surge of alanine aminotransferase (ALT) levels, which may increase the risk of adverse outcomes (e.g., decompensation, fibrosis progression, HCC, or liver-related mortality). So far, the APASL criteria to stop NA treatment is undetectable HBV DNA levels with normalization of ALT; however, this criterion for cessation of treatment is associated with various incidence rates of virological/clinical relapse and more than 40% of NA-stoppers eventually receive retreatment. A very intensive follow-up strategy and identification of low-risk patients for virological/clinical relapse by different biomarkers are the keys to stop the NA treatment safely. Recent studies suggested that decreasing HBsAg level at the end-of-treatment to < 100–200 IU/mL seems to be a useful marker for deciding when to discontinue NAs therapy. In addition, several viral and host factors have been reviewed for their potential roles in predicting clinical relapse. Finally, the APASL guidance has proposed rules to stop NA and the subsequent follow-up strategy to achieve a better prognosis after stopping NA. In general, for both HBeAg-positive and HBeAg-negative patients who have stopped treatment, these measurements should be done every 1–3 months at the minimum until 12 months. |
| Author | Su, Tung-Hung Tseng, Tai-Chung Jeng, Wen-Juei Yuen, Man-Fung Kao, Jia-Horng Ueno, Yoshiyuki Ning, Qin |
| Author_xml | – sequence: 1 givenname: Jia-Horng orcidid: 0000-0002-2442-7952 surname: Kao fullname: Kao, Jia-Horng email: kaojh@ntu.edu.tw organization: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Department of Medical Research, National Taiwan University Hospital – sequence: 2 givenname: Wen-Juei surname: Jeng fullname: Jeng, Wen-Juei organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, College of Medicine, Chang Gung University – sequence: 3 givenname: Qin surname: Ning fullname: Ning, Qin organization: Department of Infectious Disease, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology – sequence: 4 givenname: Tung-Hung surname: Su fullname: Su, Tung-Hung organization: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital – sequence: 5 givenname: Tai-Chung surname: Tseng fullname: Tseng, Tai-Chung organization: Department of Medical Research, National Taiwan University Hospital – sequence: 6 givenname: Yoshiyuki surname: Ueno fullname: Ueno, Yoshiyuki organization: Department of Gastroenterology, Faculty of Medicine, Yamagata University – sequence: 7 givenname: Man-Fung surname: Yuen fullname: Yuen, Man-Fung organization: Department of Medicine, Queen Mary Hospital, The University of Hong Kong |
| BookMark | eNp9kE1P3DAQhi0EErDwBzhZ6oUe0nrstbM5bhH9kFYqgvZsObOTxSjYqe0c-u-bJRVIHPY07-F5RjPvOTsOMRBjVyA-gRD15wxS1LISEioQUqpKH7EzaJSphF7C8WtW6pSd5_wkhNYGzBm7X9-tHzZ8N_qtC0g8Bp5LHAYfdjyM2FPM1-Wj3xJ3wfVxN1LmPnB8TDF45I80uOKLz_wL3ycKJV-wk871mS7_zwX7_fX21833avPz24-b9aZCpWWpEFCREqtOkgIjXKuWQKSXhlbdFgmXpq3bFiXKTrRgGt20iJ2T2ErT1M1KLdj1vHdI8c90V7HPPiP1vQsUx2yl1hpA1k09oR_eoU9xTNNDe8qougEDaqJWM4Up5pyos-jL9FQMJTnfWxB2X7ady7ZT2falbKsnVb5Th-SfXfp7WFKzlCc47Ci9XXXA-gcSipMf |
| CitedBy_id | crossref_primary_10_3350_cmh_2023_0194 crossref_primary_10_1097_INF_0000000000003602 crossref_primary_10_7759_cureus_32247 crossref_primary_10_1016_j_jfma_2023_02_002 crossref_primary_10_1111_apt_18416 crossref_primary_10_3350_cmh_2022_0420 crossref_primary_10_1002_jmv_28620 crossref_primary_10_1111_jgh_16923 crossref_primary_10_1097_MD_0000000000037752 crossref_primary_10_1111_apt_17644 crossref_primary_10_1097_CLD_0000000000000155 crossref_primary_10_1016_j_jmii_2024_07_012 crossref_primary_10_1016_S2352_3018_22_00123_0 crossref_primary_10_1002_hep_32479 crossref_primary_10_1111_jgh_16920 crossref_primary_10_1111_apt_17680 crossref_primary_10_3390_v14030584 crossref_primary_10_14309_ajg_0000000000002125 crossref_primary_10_1080_17474124_2021_1980385 crossref_primary_10_1080_17460441_2023_2192920 crossref_primary_10_1093_infdis_jiae541 crossref_primary_10_1016_j_jhep_2024_07_019 crossref_primary_10_3389_fpubh_2022_1037527 crossref_primary_10_1016_j_clinre_2023_102257 crossref_primary_10_1016_j_jhep_2024_08_015 crossref_primary_10_1016_j_jhep_2023_06_002 crossref_primary_10_1016_j_jcv_2022_105375 crossref_primary_10_1097_HC9_0000000000000188 crossref_primary_10_1097_HEP_0000000000000431 crossref_primary_10_11569_wcjd_v30_i15_655 crossref_primary_10_3389_fmed_2022_859430 crossref_primary_10_1111_apt_18515 crossref_primary_10_1111_liv_16029 crossref_primary_10_1007_s12072_022_10441_5 crossref_primary_10_1016_S0140_6736_22_01468_4 crossref_primary_10_1002_14651858_CD015642 crossref_primary_10_1016_j_dld_2022_04_020 crossref_primary_10_1111_apt_17222 crossref_primary_10_3389_fmicb_2022_975584 crossref_primary_10_1080_14787210_2023_2225771 crossref_primary_10_3390_jcm11092354 crossref_primary_10_1016_j_dld_2024_10_012 crossref_primary_10_1016_j_jhep_2024_10_019 crossref_primary_10_3350_cmh_2022_0084 crossref_primary_10_3350_cmh_2024_0220 crossref_primary_10_3350_cmh_2024_0101 crossref_primary_10_1016_j_asjsur_2023_04_073 crossref_primary_10_1097_QAI_0000000000003239 crossref_primary_10_1016_j_cgh_2024_09_008 crossref_primary_10_1007_s11901_024_00632_z crossref_primary_10_1080_21645515_2022_2161254 crossref_primary_10_37349_edd_2025_100565 crossref_primary_10_1016_j_jhep_2024_03_022 crossref_primary_10_1111_liv_15702 crossref_primary_10_1111_apt_17614 crossref_primary_10_1016_j_jhep_2021_11_024 crossref_primary_10_4254_wjh_v17_i1_99209 crossref_primary_10_1080_17474124_2023_2196405 crossref_primary_10_1097_CLD_0000000000000146 crossref_primary_10_3390_livers3030034 crossref_primary_10_3389_fphar_2024_1403805 crossref_primary_10_3390_v15122395 |
| Cites_doi | 10.1016/j.jhep.2009.04.003 10.1111/liv.14155 10.1016/j.cgh.2019.07.046 10.1002/hep.29187 10.1002/hep.29800 10.1111/jvh.12946 10.1111/jvh.12999 10.3390/cells9020493 10.1056/NEJMra050100 10.1093/infdis/jix690 10.1136/gutjnl-2013-305517 10.1128/AAC.01064-18 10.1111/liv.13253 10.1016/j.jhep.2010.06.016 10.3851/IMP3219 10.1517/14656566.2016.1118056 10.1016/S1499-3872(16)60064-4 10.1007/s10620-014-3486-7 10.1016/S0168-8278(20)30755-8 10.1016/j.jfma.2017.11.012 10.1136/gut.51.4.597 10.1007/s12072-019-09956-1 10.14218/JCTH.2017.00072 10.1136/gutjnl-2019-319648 10.1093/infdis/jiaa136 10.1038/ajg.2016.109 10.3851/IMP2482 10.1093/infdis/jiy350 10.1136/gutjnl-2020-321116 10.1002/hep.31026 10.1038/s41395-018-0093-9 10.3390/ijms21176366 10.1002/hep.28156 10.1007/s12072-015-9675-4 10.1007/s00535-018-1502-y 10.1093/infdis/jix025 10.1093/infdis/jiw412 10.1111/apt.13409 10.1016/j.jhep.2017.03.021 10.1111/liv.13641 10.1093/infdis/jir282 10.3851/IMP2953 10.1111/jvh.12434 10.1111/jvh.13418 10.1016/j.cgh.2018.10.037 10.1002/hep.26376 10.1007/s12072-019-09992-x 10.1016/S0168-8278(03)00394-5 10.1002/hep.29922 10.1007/s12072-012-9365-4 10.1111/jvh.13091 10.1016/j.cgh.2019.07.010 10.1002/hep.26180 10.1111/jvh.13126 10.1007/s12072-019-09943-6 10.1016/j.antiviral.2017.10.003 10.1111/1751-2980.12654 10.1016/j.cgh.2016.03.024 10.3109/00365520903394550 10.1016/j.jhep.2018.05.004 10.1002/hep.30474 10.1002/hep.26549 10.1002/hep4.1247 10.1053/j.gastro.2012.05.039 10.1016/j.cgh.2020.04.048 10.1053/j.gastro.2018.03.066 10.1053/j.gastro.2010.03.059 10.1016/j.cgh.2018.05.047 10.1002/hep.31008 10.1016/j.cgh.2015.06.002 10.1038/ctg.2017.51 10.1111/j.1365-2893.2009.01178.x 10.1002/hep.510300221 10.15585/mmwr.mm6728a2 10.1002/hep.29640 10.1111/apt.15058 10.1007/s12072-012-9344-9 10.1016/j.jhep.2016.05.029 10.1016/j.jhep.2014.05.044 10.1002/hep.26301 10.1111/apt.13150 10.3851/IMP3019 10.1002/hep.23785 10.1016/S2468-1253(19)30342-5 10.1016/j.jhep.2019.02.021 10.1111/jvh.12683 10.1016/j.jhep.2016.08.022 10.1093/cid/ciab007 10.1056/NEJMoa033364 10.1016/j.jhep.2012.04.037 10.1016/j.jhep.2012.11.039 10.1016/j.jhep.2017.07.012 10.1136/gutjnl-2014-307237 10.1016/S0140-6736(12)61425-1 10.1056/NEJMoa0802878 10.1172/JCI92812 10.1016/S2468-1253(16)30189-3 10.1111/apt.15053 10.1111/liv.13654 10.1002/hep.31525 10.1111/j.1440-1746.2011.07047.x 10.1111/apt.14560 10.1016/j.cgh.2016.07.002 10.1007/s12072-019-09989-6 10.1111/1469-0691.12605 10.1016/j.cmi.2017.12.013 10.1002/hep.29497 10.1016/j.jhep.2020.11.043 10.1111/apt.13440 10.1016/j.ijid.2015.10.019 10.1007/s12072-013-9485-5 10.1186/1471-2407-11-398 10.1111/apt.13272 10.1111/jvh.13211 10.1007/s12072-019-09991-y 10.1053/j.gastro.2012.07.014 10.1016/j.cgh.2020.04.037 10.1093/infdis/jix382 10.1016/j.jhep.2013.08.023 10.1016/j.jhep.2018.10.014 10.1002/hep.24318 10.1093/infdis/jiy097 10.1136/gutjnl-2019-318981 10.1002/hep.28438 10.3851/IMP1921 10.1111/jvh.13068 10.1016/j.cgh.2020.12.005 10.3851/IMP3256 |
| ContentType | Journal Article |
| Copyright | Asian Pacific Association for the Study of the Liver 2021 Asian Pacific Association for the Study of the Liver 2021. 2021. Asian Pacific Association for the Study of the Liver. |
| Copyright_xml | – notice: Asian Pacific Association for the Study of the Liver 2021 – notice: Asian Pacific Association for the Study of the Liver 2021. – notice: 2021. Asian Pacific Association for the Study of the Liver. |
| DBID | AAYXX CITATION 7U7 C1K K9. NAPCQ 7X8 |
| DOI | 10.1007/s12072-021-10223-5 |
| DatabaseName | CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1936-0541 |
| EndPage | 851 |
| ExternalDocumentID | 10_1007_s12072_021_10223_5 |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29I 29~ 2J2 2JN 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 53G 5GY 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG AOIJS ARMRJ AXYYD B-. BAWUL BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DIK DNIVK DPUIP DU5 E3Z EBLON EBS EIOEI EJD EN4 ESBYG EX3 F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GX1 H13 HF~ HG6 HMCUK HMJXF HRMNR HYE HZ~ IJ- IKXTQ IMOTQ IWAJR IXD IZQ J-C J0Z JBSCW JZLTJ KOV LLZTM M1P M4Y MA- NAPCQ NPVJJ NQJWS NU0 O9- O93 O9I O9J OK1 P9S PF0 PQQKQ PROAC PSQYO PT4 QOR QOS R89 R9I ROL RPM RPX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 TR2 TSG TSK TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 WOW YLTOR Z45 Z7U Z87 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT 7U7 ABRTQ C1K K9. 7X8 |
| ID | FETCH-LOGICAL-c352t-c1c3e308f2e3160ab341ee546e8fdcec46b7bbc2c2f0b16959bccfa2cb2697983 |
| IEDL.DBID | U2A |
| ISSN | 1936-0533 1936-0541 |
| IngestDate | Fri Sep 05 13:41:36 EDT 2025 Wed Sep 17 23:56:57 EDT 2025 Thu Apr 24 23:03:29 EDT 2025 Tue Jul 01 00:55:08 EDT 2025 Fri Feb 21 02:48:39 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Functional cure Antiviral therapy Treatment discontinuation Relapse Hepatitis B surface antigen Monitor Predictor Outcome Finite therapy Hepatitis B virus |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c352t-c1c3e308f2e3160ab341ee546e8fdcec46b7bbc2c2f0b16959bccfa2cb2697983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2442-7952 |
| PQID | 2563791613 |
| PQPubID | 1486344 |
| PageCount | 19 |
| ParticipantIDs | proquest_miscellaneous_2555112797 proquest_journals_2563791613 crossref_citationtrail_10_1007_s12072_021_10223_5 crossref_primary_10_1007_s12072_021_10223_5 springer_journals_10_1007_s12072_021_10223_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-01 |
| PublicationDateYYYYMMDD | 2021-08-01 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New Delhi |
| PublicationPlace_xml | – name: New Delhi – name: Tokyo |
| PublicationTitle | Hepatology international |
| PublicationTitleAbbrev | Hepatol Int |
| PublicationYear | 2021 |
| Publisher | Springer India Springer Nature B.V |
| Publisher_xml | – name: Springer India – name: Springer Nature B.V |
| References | HsuYCMoLRChangCYWuMSKaoJHWangWLAssociation between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patientsClin Gastroenterol Hepatol20161414901498.e31:CAS:528:DC%2BC28XnsVyltrk%3D27018299 MarcellinPHeathcoteEJButiMGaneEde ManRAKrastevZTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BN Engl J Med2008359244224551:CAS:528:DC%2BD1cXhsVCrurjL1905212619052126 JengWJChenYCChienRNSheenISLiawYFIncidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis BHepatology2018684254341:CAS:528:DC%2BC1cXhsVygtLvE2910813229108132 RivinoLLe BertNGillUSKunasegaranKChengYTanDZHepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationJ Clin Investig2018128668681293090505785266 LeeJChoSKimHJLeeHKoMJLimYSHigh level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: a nationwide cohort studyJ Viral Hepat2021283533631:CAS:528:DC%2BB3MXlvFyltLo%3D33051945 KaoJHBergTNucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?Gut201968210521061:CAS:528:DC%2BB3cXovV2hsb4%3D31527067 Honer Zu SiederdissenCHuiAJSukeepaisarnjaroenWTangkijvanichPSuWWNietoGEGContrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patientsJ Infect Dis20182181480148429893893 LiawYFKaoJHPiratvisuthTChanHLYChienRNLiuCJAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatol Int2012653156110.1007/s12072-012-9365-426201469 ChanHLWongGLChimAMChanHYChuSHWongVWPrediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patientsAntivir Ther201116124912571:CAS:528:DC%2BC38XitVWhtLw%3D22155906 SuTHKaoJHUnmet needs in clinical and basic hepatitis B virus researchJ Infect Dis2017216S750S7561:CAS:528:DC%2BC1cXit1ajtrvL29156048 HungCHWangJHLuSNHuTHLeeCMChenCHHepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapyJ Viral Hepat2017245996071:CAS:528:DC%2BC2sXhtVygu7zJ28130815 PapatheodoridiMPapatheodoridisGEmerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis BCells2020924931:CAS:528:DC%2BB3cXht1Klur7K7072769 Garcia-LopezMLensSPallettLJTestoniBRodriguez-TajesSRodriguez-TajesZViral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patientsJ Hepatol2021745106410741:CAS:528:DC%2BB3MXpsFGms7k%3D332784568062913 SongDSJangJWYooSHKwonJHNamSWBaeSHImproving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis BInt J Infect Dis202110.1093/cid/ciab007343320878373846 ChangTTLiawYFWuSSSchiffEHanKHLaiCLLong-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BHepatology2010528868931:CAS:528:DC%2BC3cXhtFyitr7E20683932 SetoWKHuiAJWongVWWongGLLiuKSLaiCLTreatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective studyGut2015646676721:CAS:528:DC%2BC2MXmvVyls7g%3D2483363524833635 WangCCTsengKCHsiehTYTsengTCLinHHKaoJHAssessing the durability of entecavir-treated hepatitis B using quantitative HBsAgAm J Gastroenterol2016111128612941:CAS:528:DC%2BC28XhsVOitbvN2704592327045923 LimSGAungMOChungSWSoonCSMakBHLeeKHPatient preferences for hepatitis B therapyAntivir Ther20131866367023232291 YanWWuDWangXChenTLaiQZhengQUpregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHBAntivir Ther2015205916021:CAS:528:DC%2BC28XhtFWmur3N2581446725814467 MarcellinPGaneEButiMAfdhalNSievertWJacobsonIMRegression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyLancet20133814684751:CAS:528:DC%2BC38XhvVaisrrL2323472523234725 LiawYFAntiviral therapy of chronic hepatitis B: opportunities and challenges in AsiaJ Hepatol20095140341019467727 PapatheodoridisGVManolakopoulosSSuTHSiakavellasSLiuCJKourikouASignificance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis BHepatology2018684154241:CAS:528:DC%2BC1cXhsVygtLjN28859219 NingQHanMSunYJiangJTanDHouJSwitching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)J Hepatol2014617777841:CAS:528:DC%2BC2cXhtlakur7I2491561224915612 PapatheodoridisGVRigopoulouEIPapatheodoridiMZachouKXourafasVGatselisNDARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis BAntivir Ther2018236776851:CAS:528:DC%2BC1MXhtlOku7nO3004476530044765 SarinSKKumarMEslamMGeorgeJAl MahtabMAkbarSMFLiver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology CommissionLancet Gastroenterol Hepatol2020516722831852635 SonneveldMJParkJYKaewdechASetoWKTanakaYCareyIPrediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg Levels—A Multicenter Study (CREATE)Clin Gastroenterol Hepatol202010.1016/j.cgh.2020.12.00533309804 ButiMTsaiNPetersenJFlisiakRGurelSKrastevZSeven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionDig Dis Sci201560145714641:CAS:528:DC%2BC2cXitFyhurrF2553250125532501 KuoMTHuTHHungCHWangJHLuSNTsaiKLHepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovirAliment Pharmacol Ther2019492182281:CAS:528:DC%2BC1cXis1Sru77L30484881 SarinSKKumarMLauGKAbbasZChanHLChenCJAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatol Int2016101981:STN:280:DC%2BC28vhsF2lsw%3D%3D2656312026563120 KimGALimYSAnJLeeDShimJHKimKMHBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durabilityGut201463132513321:CAS:528:DC%2BC2cXhsFGhurrI2416259324162593 LiawYFHepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreatHepatology202173284385232810321 ChenYCLiawYFPharmacotherapeutic options for hepatitis BExpert Opin Pharmacother2016173553671:CAS:528:DC%2BC2MXhvFOmtLbJ26559942 PapatheodoridisGGoulisJManolakopoulosSMargaritiAExarchosXKokkonisGChanges of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapyJ Hepatol20146062681:CAS:528:DC%2BC3sXhs1Whs7nO24012614 SetoWKLiuKSMakLYClohertyGWongDKGerschJRole of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessationGut20217077578332759300 SuzukiFHosakaTSuzukiYSezakiHAkutaNFujiyamaSLong-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in JapanJ Gastroenterol2019541821931:CAS:528:DC%2BC1cXhsFKqu7rI3013621630136216 LiuFLiuZRLiTLiuYZhangMXueYVarying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen statusJ Dig Dis2018195615711:CAS:528:DC%2BC1cXhvV2gu7jK30098114 Van HeesSBourgeoisSVan VlierbergheHSersteTFrancqueSMichielsenPStopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomesAliment Pharmacol Ther20184711701180294980785900846 van BömmelFSteinKHeyneRMöllerHPetersenJBuggischPResponse to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (LBO06)J Hepatol202073S118S119 HsuYCNguyenMHMoLRWuMSYangTHChenCCCombining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse riskAliment Pharmacol Ther2019491071151:CAS:528:DC%2BC1cXisFyks7zI3045068130450681 WangJShenTHuangXKumarGRChenXZengZSerum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and reboundJ Hepatol2016657007101:CAS:528:DC%2BC28Xht1aisbnK2724543127245431 HanMJiangJHouJTanDSunYZhaoMSustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha2a: 1 year follow-up of the OSST studyAntivir Ther2016213373441:CAS:528:DC%2BC28XitVyhur%2FI2673498426734984 LiangXGaoZXieQZhangJShengJChengJLong-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year resultsHepatol Int20191326026930977033 ChenCHHuTHWangJHLaiHCHungCHLuSNComparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapyHepatol Int2020143173253165050931650509 JengWJSheenISChenYCHsuCWChienRNChuCMOff-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patientsHepatology201358188818961:CAS:528:DC%2BC3sXhvVGku73J23744454 PapatheodoridiMHadziyannisEBerbyFZachouKTestoniBRigopoulouEPredictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis BJ Viral Hepat2020271181261:CAS:528:DC%2BB3cXhsFagtL0%3D3156274831562748 RyuSHChungYHChoiMHKimJAShinJWJangMKLong-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective studyJ Hepatol2003396146191:CAS:528:DC%2BD3sXntVGhsbk%3 C Honer Zu Siederdissen (10223_CR54) 2016; 214 M Bourliere (10223_CR97) 2017; 2 M Garcia-Lopez (10223_CR56) 2021; 74 WJ Jeng (10223_CR101) 2013; 58 NA Terrault (10223_CR10) 2018; 67 J Wang (10223_CR114) 2016; 65 YW Qiu (10223_CR127) 2016; 43 CH Chen (10223_CR51) 2020; 14 G Papatheodoridis (10223_CR44) 2015; 22 JL Hou (10223_CR27) 2020; 18 S Chevaliez (10223_CR42) 2013; 58 SJ Hadziyannis (10223_CR47) 2012; 143 SM Chiu (10223_CR105) 2020; 18 WK Seto (10223_CR111) 2021; 70 F Rinker (10223_CR55) 2018; 69 YF Liaw (10223_CR70) 2004; 351 SG Lim (10223_CR28) 2002; 51 TN Tseng (10223_CR102) 2020; 18 HL Chan (10223_CR46) 2011; 16 L Rivino (10223_CR57) 2018; 128 SG Lim (10223_CR25) 2013; 18 L Wang (10223_CR123) 2010; 17 YF Lam (10223_CR130) 2017; 8 J Lee (10223_CR23) 2021; 28 SK Sarin (10223_CR32) 2020; 5 TT Chang (10223_CR68) 2010; 52 YC Hsu (10223_CR106) 2016; 14 F Liu (10223_CR125) 2018; 19 H Kranidioti (10223_CR116) 2019; 26 F van Bömmel (10223_CR49) 2020; 73 GA Kim (10223_CR6) 2014; 63 TH Su (10223_CR103) 2018; 217 S Sheppard-Law (10223_CR24) 2018; 23 TH Su (10223_CR3) 2016; 36 M Han (10223_CR92) 2016; 21 J Wang (10223_CR73) 2014; 8 P Marcellin (10223_CR26) 2019; 39 YF Liaw (10223_CR13) 1999; 30 CH Chen (10223_CR52) 2020; 10 JG Reijnders (10223_CR78) 2010; 139 CH Chen (10223_CR85) 2015; 13 M Han (10223_CR89) 2017; 147 H Chi (10223_CR83) 2015; 41 YS Lim (10223_CR66) 2017; 66 N Ford (10223_CR21) 2018; 2 HW Lee (10223_CR64) 2019; 17 Q Ning (10223_CR87) 2019; 26 WK Seto (10223_CR77) 2013; 58 G Papatheodoridis (10223_CR43) 2014; 60 Y Hutin (10223_CR2) 2018; 67 J Cao (10223_CR124) 2017; 215 KK Lee (10223_CR29) 2012; 27 S Van Hees (10223_CR79) 2018; 47 W Chotiyaputta (10223_CR20) 2011; 54 L Xie (10223_CR30) 2018; 68 T Hosaka (10223_CR71) 2013; 58 JW Shin (10223_CR22) 2018; 113 TC Yip (10223_CR5) 2019; 70 SH Ryu (10223_CR122) 2003; 39 X Liang (10223_CR62) 2019; 13 Q Ning (10223_CR91) 2014; 61 European Association for the Study of the Liver (10223_CR8) 2017; 67 GV Papatheodoridis (10223_CR34) 2018; 68 A Ono (10223_CR60) 2012; 57 A Shi (10223_CR90) 2018; 25 D Wu (10223_CR94) 2019; 13 SK Sarin (10223_CR11) 2016; 10 CT Yeh (10223_CR14) 2011; 11 W Yan (10223_CR88) 2015; 20 10223_CR95 R Fan (10223_CR120) 2020; 222 WK Seto (10223_CR80) 2015; 64 C Hongthanakorn (10223_CR19) 2011; 53 YC Chen (10223_CR4) 2016; 17 DS Song (10223_CR128) 2021 10223_CR16 YF Liaw (10223_CR59) 2021; 73 TH Su (10223_CR98) 2017; 216 WJ Jeng (10223_CR7) 2018; 68 P Hu (10223_CR93) 2018; 6 CH Hung (10223_CR37) 2017; 24 M Buti (10223_CR45) 2015; 60 CC Wang (10223_CR107) 2016; 111 YF Liaw (10223_CR109) 2018; 154 KS Liem (10223_CR81) 2019; 68 World Health Organization (10223_CR1) 2017 F Suzuki (10223_CR61) 2019; 54 H Chi (10223_CR113) 2019; 17 J Ahn (10223_CR38) 2016; 43 CH Chen (10223_CR104) 2018; 24 GL Wong (10223_CR72) 2013; 58 YH Kuo (10223_CR40) 2010; 45 ML Chang (10223_CR39) 2015; 42 K Ma (10223_CR74) 2012; 6 NA Terrault (10223_CR9) 2016; 63 R Fan (10223_CR121) 2020; 18 F van Bommel (10223_CR131) 2018; 38 CH Tseng (10223_CR112) 2018; 117 P Marcellin (10223_CR63) 2008; 359 M Papatheodoridi (10223_CR108) 2020; 27 G Hirode (10223_CR50) 2020; 72 L Osterberg (10223_CR18) 2005; 353 M Papatheodoridi (10223_CR118) 2019; 26 YF Liaw (10223_CR31) 2009; 51 C Boni (10223_CR53) 2012; 143 M Buti (10223_CR17) 2018; 38 T Chen (10223_CR75) 2019; 16 CL Zimmer (10223_CR58) 2018; 217 D He (10223_CR126) 2014; 20 MJ Sonneveld (10223_CR119) 2020 ML Wang (10223_CR15) 2016; 15 MT Kuo (10223_CR82) 2019; 49 C Honer Zu Siederdissen (10223_CR117) 2018; 218 AL Cathcart (10223_CR67) 2018; 62 YF Liaw (10223_CR12) 2012; 6 WJ Jeng (10223_CR84) 2016; 14 I Carey (10223_CR115) 2016; 72 YF Liaw (10223_CR33) 2019; 13 R Zoutendijk (10223_CR41) 2011; 204 P Marcellin (10223_CR69) 2013; 381 JH Kao (10223_CR100) 2019; 68 M Papatheodoridi (10223_CR99) 2020; 9 CL Lai (10223_CR76) 2017; 66 P Lampertico (10223_CR96) 2019; 26 T Berg (10223_CR48) 2017; 67 G Papatheodoridis (10223_CR35) 2016; 63 YS Lim (10223_CR65) 2019; 71 YC Hsu (10223_CR110) 2019; 49 J Liu (10223_CR86) 2019; 70 YC Chen (10223_CR36) 2015; 42 GV Papatheodoridis (10223_CR129) 2018; 23 |
| References_xml | – reference: SarinSKKumarMLauGKAbbasZChanHLChenCJAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatol Int2016101981:STN:280:DC%2BC28vhsF2lsw%3D%3D2656312026563120 – reference: ChenTYangZChoudhuryAKAl MahtabMLiJChenYComplications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific regionHepatol Int2019166695705 – reference: RyuSHChungYHChoiMHKimJAShinJWJangMKLong-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective studyJ Hepatol2003396146191:CAS:528:DC%2BD3sXntVGhsbk%3D12971973 – reference: Lai MW, Liang KH, Yeh CT. Hepatitis B virus preS/S truncation mutant rtM204I/sW196* increases carcinogenesis through deregulated HIF1A, MGST2, and TGFbi. Int J Mol Sci. 2020:6366 – reference: MarcellinPGaneEButiMAfdhalNSievertWJacobsonIMRegression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyLancet20133814684751:CAS:528:DC%2BC38XhvVaisrrL2323472523234725 – reference: LiemKSFungSWongDKYimCNoureldinSChenJLimited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)Gut201968220622131:CAS:528:DC%2BB3cXovV2hsbk%3D3146255431462554 – reference: Garcia-LopezMLensSPallettLJTestoniBRodriguez-TajesSRodriguez-TajesZViral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patientsJ Hepatol2021745106410741:CAS:528:DC%2BB3MXpsFGms7k%3D332784568062913 – reference: BergTSimonKGMaussSSchottEHeyneRKlassDMLong-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients—FINITE studyJ Hepatol2017679189241:CAS:528:DC%2BC2sXht1Ggt7zF2873613928736139 – reference: PapatheodoridiMPapatheodoridisGCan we stop nucleoside analogues before HBsAg loss?J Viral Hepat2019269369411:CAS:528:DC%2BC1MXhsVarsb3M30803099 – reference: Honer Zu SiederdissenCHuiAJSukeepaisarnjaroenWTangkijvanichPSuWWNietoGEGContrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patientsJ Infect Dis20182181480148429893893 – reference: QiuYWHuangLHYangWLWangZZhangBLiYGHepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patientsInt J Infect Dis20164343481:CAS:528:DC%2BC2MXhvVKmsb%2FE26523639 – reference: ChenCHChenCYWangJHLaiHCHungCHLuSNComparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan—a retrospective studyAm J Cancer Res202010388238951:CAS:528:DC%2BB3MXmvVajsLw%3D332942747716174 – reference: LimYSLeeYSGwakGYByunKSKimYJChoiJMonotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trialHepatology2017667727831:CAS:528:DC%2BC2sXhtlOhsb3J2837041928370419 – reference: HosakaTSuzukiFKobayashiMSekoYKawamuraYSezakiHLong-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infectionHepatology201358981071:CAS:528:DC%2BC3sXhtVaju7vP2321304023213040 – reference: LiawYFChienRNYehCTTsaiSLChuCMAcute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology1999305675721:CAS:528:DyaK1MXlt1ajsLg%3D10421670 – reference: Honer Zu SiederdissenCRinkerFMaasoumyBWiegandSBFilmannNFalkCSViral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis BJ Infect Dis20162141492149727609808 – reference: ChenCHHungCHHuTHWangJHLuSNSuPFAssociation between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infectionClin Gastroenterol Hepatol20151319841992.e11:CAS:528:DC%2BC2MXht1ygsL%2FO2607349226073492 – reference: SuTHHuTHChenCYHuangYHChuangWLLinCCFour-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsLiver Int201636175517641:CAS:528:DC%2BC28XhvFelsrzI2763413427634134 – reference: RivinoLLe BertNGillUSKunasegaranKChengYTanDZHepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationJ Clin Investig2018128668681293090505785266 – reference: NingQHanMSunYJiangJTanDHouJSwitching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)J Hepatol2014617777841:CAS:528:DC%2BC2cXhtlakur7I2491561224915612 – reference: XieLYinJXiaRZhuangGCost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosisHepatology2018681476148629633304 – reference: WangJMaKHanMGuoWHuangJYangDNucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM modelHepatol Int2014864711:CAS:528:DC%2BC2cXitVOmtr7K26202407 – reference: HadziyannisSJSevastianosVRaptiIVassilopoulosDHadziyannisESustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovirGastroenterology2012143629636.e11:CAS:528:DC%2BC38XhtV2nurrP – reference: SetoWKWongDKFungJHuangFYLaiCLYuenMFReduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapyHepatology2013589239311:CAS:528:DC%2BC3sXhtlOkt73K23468172 – reference: OnoASuzukiFKawamuraYSezakiHHosakaTAkutaNLong-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patientsJ Hepatol2012575085141:CAS:528:DC%2BC38Xht1ensrzP22659518 – reference: Sheppard-LawSZablotska-ManosIKermeenMHoldawaySLeeAGeorgeJFactors associated with non-adherence to HBV antiviral therapyAntivir Ther2018234254331:CAS:528:DC%2BB3cXht1ertbnI29355830 – reference: PapatheodoridisGGoulisJManolakopoulosSMargaritiAExarchosXKokkonisGChanges of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapyJ Hepatol20146062681:CAS:528:DC%2BC3sXhs1Whs7nO24012614 – reference: HutinYNasrullahMEasterbrookPNguimfackBDBurroneEAverhoffFAccess to treatment for hepatitis B virus infection—Worldwide, 2016MMWR Morb Mortal Wkly Rep201867773777300254136054001 – reference: LeeJChoSKimHJLeeHKoMJLimYSHigh level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: a nationwide cohort studyJ Viral Hepat2021283533631:CAS:528:DC%2BB3MXlvFyltLo%3D33051945 – reference: LimYSGwakGYChoiJLeeYSByunKSKimYJMonotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trialJ Hepatol20197135441:CAS:528:DC%2BC1MXms1Onsrw%3D3087694630876946 – reference: WuDWangPHanMChenYChenXXiaQSequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor studyHepatol Int2019135735863117241531172415 – reference: HungCHWangJHLuSNHuTHLeeCMChenCHHepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapyJ Viral Hepat2017245996071:CAS:528:DC%2BC2sXhtVygu7zJ28130815 – reference: van BommelFBergTStopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis BLiver Int201838Suppl 1909629427489 – reference: WangJShenTHuangXKumarGRChenXZengZSerum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and reboundJ Hepatol2016657007101:CAS:528:DC%2BC28Xht1aisbnK2724543127245431 – reference: LamYFSetoWKWongDCheungKSFungJMakLYSeven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levelsClin Transl Gastroenterol20178e1251:CAS:528:DC%2BC2sXhslajtrrP2907267329072673 – reference: LiawYFSungJJChowWCFarrellGLeeCZYuenHLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med2004351152115311:CAS:528:DC%2BD2cXot1Kls7w%3D1547021515470215 – reference: ShiAZhangXXiaoFZhuLYanWHanMCD56(bright) natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2aJ Viral Hepat201825135213621:CAS:528:DC%2BC1cXitVWrurnF2988883929888839 – reference: SonneveldMJParkJYKaewdechASetoWKTanakaYCareyIPrediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg Levels—A Multicenter Study (CREATE)Clin Gastroenterol Hepatol202010.1016/j.cgh.2020.12.00533309804 – reference: HuPShangJZhangWGongGLiYChenXHBsAg loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch studyJ Clin Transl Hepatol2018625342957702929577029 – reference: WangCCTsengKCHsiehTYTsengTCLinHHKaoJHAssessing the durability of entecavir-treated hepatitis B using quantitative HBsAgAm J Gastroenterol2016111128612941:CAS:528:DC%2BC28XhsVOitbvN2704592327045923 – reference: SuTHYangHCTsengTCLiouJMLiuCHChenCLDistinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapyJ Infect Dis2018217119312011:CAS:528:DC%2BC1MXmsFGlt7c%3D29300980 – reference: LimSGWaiCTRajnakovaAKajijiTGuanRFatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis BGut2002515975991:STN:280:DC%2BD38vntlSmsg%3D%3D122350871773395 – reference: ButiMRiveiro-BarcielaMEstebanRLong-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis BLiver Int201838Suppl 1848929427500 – reference: ChenYCPengCYJengWJChienRNLiawYFClinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosisAliment Pharmacol Ther201542118211911:CAS:528:DC%2BC2MXhs1Ohu73O26381928 – reference: JengWJSheenISChenYCHsuCWChienRNChuCMOff-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patientsHepatology201358188818961:CAS:528:DC%2BC3sXhvVGku73J23744454 – reference: ChotiyaputtaWPetersonCDitahFAGoodwinDLokASPersistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis BJ Hepatol20115412181:CAS:528:DC%2BC3cXhsV2gur3J20888661 – reference: ButiMTsaiNPetersenJFlisiakRGurelSKrastevZSeven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionDig Dis Sci201560145714641:CAS:528:DC%2BC2cXitFyhurrF2553250125532501 – reference: CathcartALChanHLBhardwajNLiuYMarcellinPPanCQNo resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infectionAntimicrob Agents Chemother20186210e01064181:CAS:528:DC%2BC1cXitlKnt7jJ300380446153810 – reference: ChangTTLiawYFWuSSSchiffEHanKHLaiCLLong-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BHepatology2010528868931:CAS:528:DC%2BC3cXhtFyitr7E20683932 – reference: LiawYFKaoJHPiratvisuthTChanHLYChienRNLiuCJAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatol Int2012653156110.1007/s12072-012-9365-426201469 – reference: WongGLChanHLMakCWLeeSKIpZMLamATEntecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosisHepatology201358153715471:CAS:528:DC%2BC3sXhslWqsLjK2338981023389810 – reference: WangLLiuFLiuYDLiXYWangJBZhangZHStringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patientsJ Viral Hepat2010172983041:STN:280:DC%2BC3czhsFCmsQ%3D%3D19758278 – reference: SarinSKKumarMEslamMGeorgeJAl MahtabMAkbarSMFLiver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology CommissionLancet Gastroenterol Hepatol2020516722831852635 – reference: PapatheodoridisGVRigopoulouEIPapatheodoridiMZachouKXourafasVGatselisNDARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis BAntivir Ther2018236776851:CAS:528:DC%2BC1MXhtlOku7nO3004476530044765 – reference: LamperticoPBrunettoMRCraxiAGaetaGBRizzettoMRozziAAdd-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype DJ Viral Hepat2019261181251:CAS:528:DC%2BC1MXjsFyksw%3D%3D3018759930187599 – reference: KranidiotiHManolakopoulosSKontosGBreenMSKourikouADeutschMImmunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis BJ Viral Hepat2019266977091:CAS:528:DC%2BC1MXpvVOksbc%3D30702196 – reference: ChiHHansenBEYimCArendsPAbu-AmaraMvan der EijkAAReduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis BAliment Pharmacol Ther2015418678761:CAS:528:DC%2BC2MXlslKis7k%3D25752878 – reference: Meifang Han DW, Deming Tan, Yongping Chen, Xinyue Chen, Xiaoguang Dou, Ke Ma, Li Sun, Qin Ning. Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis. Hepatology. 2017;66, S1, 13A – reference: ChenCHHungCHWangJHLuSNHuTHLeeCMLong-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patientsClin Microbiol Infect20182499710031:CAS:528:DC%2BC1cXhsF2hs7w%3D29288020 – reference: RinkerFZimmerCLHoner Zu SiederdissenCMannsMPKraftARMWedemeyerHHepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis BJ Hepatol2018695845931:CAS:528:DC%2BC1cXhtFGltrvE2975833329758333 – reference: TerraultNABzowejNHChangKMHwangJPJonasMMMuradMHAASLD guidelines for treatment of chronic hepatitis BHepatology2016632612832656606426566064 – reference: LiawYFJengWJChangMLHBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patientsGastroenterology20181542280228129746811 – reference: KaoJHBergTNucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop?Gut201968210521061:CAS:528:DC%2BB3cXovV2hsb4%3D31527067 – reference: ZoutendijkRHansenBEvan VuurenAJBoucherCAJanssenHLSerum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg lossJ Infect Diss20112044154181:CAS:528:DC%2BC3MXovVKqsbw%3D – reference: MarcellinPWongDKSievertWBuggischPPetersenJFlisiakRTen-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionLiver Int201939186818751:CAS:528:DC%2BC1MXhvVaksL7J3113605231136052 – reference: ChevaliezSHezodeCBahramiSGrareMPawlotskyJMLong-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikelyJ Hepatol2013586766831:CAS:528:DC%2BC3sXhtF2jtb4%3D – reference: ChanHLWongGLChimAMChanHYChuSHWongVWPrediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patientsAntivir Ther201116124912571:CAS:528:DC%2BC38XitVWhtLw%3D22155906 – reference: JengWJChenYCSheenISLinCLHuTHChienRNClinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patientsClin Gastroenterol Hepatol20161418131820.e11:CAS:528:DC%2BC28XhsFentb7F2740496927404969 – reference: LeeKKWuDBChowPYLeeVWLiHEconomic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong KongJ Gastroenterol Hepatol2012271167117422141402 – reference: TsengTNHuTHWangJHKuoYHHungCHLuSNIncidence and Factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU/mLClin Gastroenterol Hepatol20201828032812.e28021:CAS:528:DC%2BB3cXhtVOltrjE32360818 – reference: YehCTChenTHsuCWChenYCLaiMWLiangKHEmergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis BBMC Cancer2011113981:CAS:528:DC%2BC3MXhtlajs7zP219334463184121 – reference: KuoYHChenCHWangJHHungCHTsengPLLuSNExtended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversionScand J Gastroenterol20104575811:CAS:528:DC%2BD1MXhs1aqt7jF20030580 – reference: LiawYFAntiviral therapy of chronic hepatitis B: opportunities and challenges in AsiaJ Hepatol20095140341019467727 – reference: OsterbergLBlaschkeTAdherence to medicationN Engl J Med20053534874971:CAS:528:DC%2BD2MXntVCisL0%3D16079372 – reference: MaKGuoWHanMChenGChenTWuZEntecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression modelHepatol Int2012673574326201523 – reference: PapatheodoridiMPapatheodoridisGEmerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis BCells2020924931:CAS:528:DC%2BB3cXht1Klur7K7072769 – reference: LiawYFHepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreatHepatology202173284385232810321 – reference: Van HeesSBourgeoisSVan VlierbergheHSersteTFrancqueSMichielsenPStopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomesAliment Pharmacol Ther20184711701180294980785900846 – reference: LiuJLiTZhangLXuAThe role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic reviewHepatology201970104510551:CAS:528:DC%2BC1MXhslWgtrzP30561829 – reference: LeeHWParkJYLeeJWYoonKTKimCWParkHLong-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hbv infectionClin Gastroenterol Hepatol20191713481355.e21:CAS:528:DC%2BC1MXntFajtg%3D%3D30613003 – reference: FanRZhouBXuMTanDNiuJWangHAssociation Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue TherapyClin Gastroenterol Hepatol202018719727.e71:CAS:528:DC%2BC1MXhvVShurzK3136211931362119 – reference: TsengCHHsuYCChangCYTsengTCWuMSLinJTQuantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis BJ Formos Med Assoc20181179159211:CAS:528:DC%2BC2sXhvFCrsb7L29249417 – reference: JengWJChenYCChienRNSheenISLiawYFIncidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis BHepatology2018684254341:CAS:528:DC%2BC1cXhsVygtLvE2910813229108132 – reference: PapatheodoridisGTriantosCHadziyannisEZisimopoulosKGeorgiouAVoulgarisTSerum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarateJ Viral Hepat201522107910871:CAS:528:DC%2BC2MXhslegt7fF26146764 – reference: CaoJChiHYuTLiZHansenBEZhangXOff-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop studyJ Infect Dis20172155815891:CAS:528:DC%2BC1cXitFCru7zO28329347 – reference: PapatheodoridisGVManolakopoulosSSuTHSiakavellasSLiuCJKourikouASignificance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis BHepatology2018684154241:CAS:528:DC%2BC1cXhsVygtLjN28859219 – reference: HsuYCMoLRChangCYWuMSKaoJHWangWLAssociation between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patientsClin Gastroenterol Hepatol20161414901498.e31:CAS:528:DC%2BC28XnsVyltrk%3D27018299 – reference: BourliereMRabiegaPGanne-CarrieNSerfatyLMarcellinPBartheYEffect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialLancet Gastroenterol Hepatol201721771882840413328404133 – reference: LiawYFFinite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shiftHepatol Int2019136656733155960431559604 – reference: SongDSJangJWYooSHKwonJHNamSWBaeSHImproving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis BInt J Infect Dis202110.1093/cid/ciab007343320878373846 – reference: van BömmelFSteinKHeyneRMöllerHPetersenJBuggischPResponse to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (LBO06)J Hepatol202073S118S119 – reference: KimGALimYSAnJLeeDShimJHKimKMHBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durabilityGut201463132513321:CAS:528:DC%2BC2cXhsFGhurrI2416259324162593 – reference: LaiCLWongDIpPKopaniszenMSetoWKFungJReduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis BJ Hepatol2017662752811:CAS:528:DC%2BC28XhslWjt7rI2763984427639844 – reference: European Association for the Study of the LiverElectronic address: easloffice@easloffice.eu; European Association for the Study of the LiverEASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJ Hepatol2017672370398 – reference: ChiHLiZHansenBEYuTZhangXSunJSerum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapyClin Gastroenterol Hepatol2019171821911:CAS:528:DC%2BC1cXhvVSitbfO29902645 – reference: HouJLZhaoWLeeCHannHWPengCYTanwandeeTOutcomes of long-term treatment of chronic hbv infection with entecavir or other agents from a randomized trial in 24 countriesClin Gastroenterol Hepatol202018457467.e211:CAS:528:DC%2BC1MXitV2ms7%2FN3130680031306800 – reference: SetoWKHuiAJWongVWWongGLLiuKSLaiCLTreatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective studyGut2015646676721:CAS:528:DC%2BC2MXmvVyls7g%3D2483363524833635 – reference: KuoMTHuTHHungCHWangJHLuSNTsaiKLHepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovirAliment Pharmacol Ther2019492182281:CAS:528:DC%2BC1cXis1Sru77L30484881 – reference: HanMLiYWuWZhangYYanWLuoXAltered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infectionAntiviral Res201714775851:CAS:528:DC%2BC2sXhs1Kqs7nE28988797 – reference: ZimmerCLRinkerFHöner Zu SiederdissenCMannsMPWedemeyerHCornbergMIncreased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg lossJ Infect Dis2018217165616661:CAS:528:DC%2BC1MXhtVCmsrjL2947149729471497 – reference: ChenCHHuTHWangJHLaiHCHungCHLuSNComparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapyHepatol Int2020143173253165050931650509 – reference: LiuFLiuZRLiTLiuYZhangMXueYVarying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen statusJ Dig Dis2018195615711:CAS:528:DC%2BC1cXhvV2gu7jK30098114 – reference: SetoWKLiuKSMakLYClohertyGWongDKGerschJRole of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessationGut20217077578332759300 – reference: LimSGAungMOChungSWSoonCSMakBHLeeKHPatient preferences for hepatitis B therapyAntivir Ther20131866367023232291 – reference: PapatheodoridisGVlachogiannakosICholongitasEWursthornKThomadakisCTouloumiGDiscontinuation of oral antivirals in chronic hepatitis B: a systematic reviewHepatology201663148114921:CAS:528:DC%2BC28XmsVCqs78%3D2710014527100145 – reference: LiangXGaoZXieQZhangJShengJChengJLong-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year resultsHepatol Int20191326026930977033 – reference: HongthanakornCChotiyaputtaWOberhelmanKFontanaRJMarreroJALicariTVirological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceHepatology2011531854186321618260 – reference: AhnJLeeHMLimJKPanCQNguyenMHRay KimWEntecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US—the ENUMERATE studyAliment Pharmacol Ther2016431341441:CAS:528:DC%2BC2MXhvF2lurfN26510638 – reference: NingQWuDWangGQRenHGaoZLHuPRoadmap to functional cure of chronic hepatitis B: an expert consensusJ Viral Hepat201926114611553108747931087479 – reference: World Health OrganizationGlobal hepatitis report, 20172017GenevaSwitzerland World Health Organization – reference: HirodeGChoiHSJSuT-HWongGL-HSetoW-KVan HeesSHBsAg Loss is higher among caucasians compared to asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study) (O023)Hepatology20207219A20A – reference: YanWWuDWangXChenTLaiQZhengQUpregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHBAntivir Ther2015205916021:CAS:528:DC%2BC28XhtFWmur3N2581446725814467 – reference: YipTCWongGLChanHLTseYKLamKLLuiGCHBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analoguesJ Hepatol2019703613701:CAS:528:DC%2BC1cXit1CrtrfN3036789930367899 – reference: MarcellinPHeathcoteEJButiMGaneEde ManRAKrastevZTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BN Engl J Med2008359244224551:CAS:528:DC%2BD1cXhsVCrurjL1905212619052126 – reference: HeDGuoSZhuPTaoSLiMHuangHLong-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patientsClin Microbiol Infect201420O687O6931:CAS:528:DC%2BC2cXitVeku77J25469947 – reference: BoniCLaccabueDLamperticoPGiubertiTViganoMSchivazappaSRestored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analoguesGastroenterology2012143963973.e91:CAS:528:DC%2BC38XhsVSlur%2FK2279624122796241 – reference: SuzukiFHosakaTSuzukiYSezakiHAkutaNFujiyamaSLong-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in JapanJ Gastroenterol2019541821931:CAS:528:DC%2BC1cXhsFKqu7rI3013621630136216 – reference: FordNScourseRLemoineMHutinYBulterysMShubberZAdherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysisHepatol Commun2018211601167302884706167073 – reference: HsuYCNguyenMHMoLRWuMSYangTHChenCCCombining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse riskAliment Pharmacol Ther2019491071151:CAS:528:DC%2BC1cXisFyks7zI3045068130450681 – reference: TerraultNALokASFMcMahonBJChangKMHwangJPJonasMMUpdate on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology201867156015992940532929405329 – reference: ShinJWJungSWLeeSBLeeBUParkBRParkEJMedication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavirAm J Gastroenterol201811399810081:CAS:528:DC%2BC1cXht1Cgt7nI29880971 – reference: FanRPengJXieQTanDXuMNiuJCombining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis BJ Infect Dis20202226116181:CAS:528:DC%2BB3cXhsV2ksLbK3221177632211776 – reference: SuTHKaoJHUnmet needs in clinical and basic hepatitis B virus researchJ Infect Dis2017216S750S7561:CAS:528:DC%2BC1cXit1ajtrvL29156048 – reference: CareyIGerschJWangBMoigboiCKuhnsMClohertyGPre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapyHepatology20167214257 – reference: ChenYCLiawYFPharmacotherapeutic options for hepatitis BExpert Opin Pharmacother2016173553671:CAS:528:DC%2BC2MXhvFOmtLbJ26559942 – reference: WangMLTangHNucleos(t)ide analogues causes HBV S gene mutations and carcinogenesisHepatobiliary Pancreat Dis Int20161557958627919846 – reference: ChangMLLiawYFHadziyannisSJSystematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis BAliment Pharmacol Ther2015422432571:CAS:528:DC%2BC2MXhtFCiu73J26151841 – reference: PapatheodoridiMHadziyannisEBerbyFZachouKTestoniBRigopoulouEPredictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis BJ Viral Hepat2020271181261:CAS:528:DC%2BB3cXhsFagtL0%3D3156274831562748 – reference: HanMJiangJHouJTanDSunYZhaoMSustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha2a: 1 year follow-up of the OSST studyAntivir Ther2016213373441:CAS:528:DC%2BC28XitVyhur%2FI2673498426734984 – reference: ReijndersJGPerquinMJZhangNHansenBEJanssenHLNucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis BGastroenterology20101394914981:CAS:528:DC%2BC3cXpsVGnu7s%3D20381492 – reference: ChiuSMKuoYHWangJHHungCHHuTHLuSNAssociations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapyClin Gastroenterol Hepatol20201829892997.e29831:CAS:528:DC%2BB3cXht1KgtbfM32353534 – volume: 51 start-page: 403 year: 2009 ident: 10223_CR31 publication-title: J Hepatol doi: 10.1016/j.jhep.2009.04.003 – volume: 39 start-page: 1868 year: 2019 ident: 10223_CR26 publication-title: Liver Int doi: 10.1111/liv.14155 – volume: 18 start-page: 719 year: 2020 ident: 10223_CR121 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.07.046 – volume: 66 start-page: 772 year: 2017 ident: 10223_CR66 publication-title: Hepatology doi: 10.1002/hep.29187 – volume: 67 start-page: 1560 year: 2018 ident: 10223_CR10 publication-title: Hepatology doi: 10.1002/hep.29800 – volume: 25 start-page: 1352 year: 2018 ident: 10223_CR90 publication-title: J Viral Hepat doi: 10.1111/jvh.12946 – volume: 26 start-page: 118 year: 2019 ident: 10223_CR96 publication-title: J Viral Hepat doi: 10.1111/jvh.12999 – volume: 9 start-page: 493 issue: 2 year: 2020 ident: 10223_CR99 publication-title: Cells doi: 10.3390/cells9020493 – volume: 353 start-page: 487 year: 2005 ident: 10223_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMra050100 – volume: 217 start-page: 1193 year: 2018 ident: 10223_CR103 publication-title: J Infect Dis doi: 10.1093/infdis/jix690 – volume: 63 start-page: 1325 year: 2014 ident: 10223_CR6 publication-title: Gut doi: 10.1136/gutjnl-2013-305517 – volume: 62 start-page: e01064 issue: 10 year: 2018 ident: 10223_CR67 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01064-18 – volume: 36 start-page: 1755 year: 2016 ident: 10223_CR3 publication-title: Liver Int doi: 10.1111/liv.13253 – volume: 54 start-page: 12 year: 2011 ident: 10223_CR20 publication-title: J Hepatol doi: 10.1016/j.jhep.2010.06.016 – volume: 23 start-page: 425 year: 2018 ident: 10223_CR24 publication-title: Antivir Ther doi: 10.3851/IMP3219 – volume: 17 start-page: 355 year: 2016 ident: 10223_CR4 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2016.1118056 – volume: 15 start-page: 579 year: 2016 ident: 10223_CR15 publication-title: Hepatobiliary Pancreat Dis Int doi: 10.1016/S1499-3872(16)60064-4 – volume: 60 start-page: 1457 year: 2015 ident: 10223_CR45 publication-title: Dig Dis Sci doi: 10.1007/s10620-014-3486-7 – volume: 73 start-page: S118 year: 2020 ident: 10223_CR49 publication-title: J Hepatol doi: 10.1016/S0168-8278(20)30755-8 – volume: 10 start-page: 3882 year: 2020 ident: 10223_CR52 publication-title: Am J Cancer Res – volume: 117 start-page: 915 year: 2018 ident: 10223_CR112 publication-title: J Formos Med Assoc doi: 10.1016/j.jfma.2017.11.012 – volume: 51 start-page: 597 year: 2002 ident: 10223_CR28 publication-title: Gut doi: 10.1136/gut.51.4.597 – volume: 13 start-page: 573 year: 2019 ident: 10223_CR94 publication-title: Hepatol Int doi: 10.1007/s12072-019-09956-1 – volume: 6 start-page: 25 year: 2018 ident: 10223_CR93 publication-title: J Clin Transl Hepatol doi: 10.14218/JCTH.2017.00072 – volume: 68 start-page: 2105 year: 2019 ident: 10223_CR100 publication-title: Gut doi: 10.1136/gutjnl-2019-319648 – volume: 222 start-page: 611 year: 2020 ident: 10223_CR120 publication-title: J Infect Dis doi: 10.1093/infdis/jiaa136 – volume: 111 start-page: 1286 year: 2016 ident: 10223_CR107 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2016.109 – volume: 18 start-page: 663 year: 2013 ident: 10223_CR25 publication-title: Antivir Ther doi: 10.3851/IMP2482 – volume: 218 start-page: 1480 year: 2018 ident: 10223_CR117 publication-title: J Infect Dis doi: 10.1093/infdis/jiy350 – volume: 70 start-page: 775 year: 2021 ident: 10223_CR111 publication-title: Gut doi: 10.1136/gutjnl-2020-321116 – volume: 72 start-page: 42 issue: 1 year: 2016 ident: 10223_CR115 publication-title: Hepatology doi: 10.1002/hep.31026 – volume: 113 start-page: 998 year: 2018 ident: 10223_CR22 publication-title: Am J Gastroenterol doi: 10.1038/s41395-018-0093-9 – ident: 10223_CR16 doi: 10.3390/ijms21176366 – volume: 63 start-page: 261 year: 2016 ident: 10223_CR9 publication-title: Hepatology doi: 10.1002/hep.28156 – volume: 10 start-page: 1 year: 2016 ident: 10223_CR11 publication-title: Hepatol Int doi: 10.1007/s12072-015-9675-4 – volume: 54 start-page: 182 year: 2019 ident: 10223_CR61 publication-title: J Gastroenterol doi: 10.1007/s00535-018-1502-y – volume: 215 start-page: 581 year: 2017 ident: 10223_CR124 publication-title: J Infect Dis doi: 10.1093/infdis/jix025 – volume: 214 start-page: 1492 year: 2016 ident: 10223_CR54 publication-title: J Infect Dis doi: 10.1093/infdis/jiw412 – volume: 42 start-page: 1182 year: 2015 ident: 10223_CR36 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13409 – volume: 67 start-page: 370 issue: 2 year: 2017 ident: 10223_CR8 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 38 start-page: 84 issue: Suppl 1 year: 2018 ident: 10223_CR17 publication-title: Liver Int doi: 10.1111/liv.13641 – volume: 204 start-page: 415 year: 2011 ident: 10223_CR41 publication-title: J Infect Diss doi: 10.1093/infdis/jir282 – volume: 20 start-page: 591 year: 2015 ident: 10223_CR88 publication-title: Antivir Ther doi: 10.3851/IMP2953 – volume: 22 start-page: 1079 year: 2015 ident: 10223_CR44 publication-title: J Viral Hepat doi: 10.1111/jvh.12434 – volume: 28 start-page: 353 year: 2021 ident: 10223_CR23 publication-title: J Viral Hepat doi: 10.1111/jvh.13418 – volume: 17 start-page: 1348 year: 2019 ident: 10223_CR64 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.10.037 – volume: 58 start-page: 923 year: 2013 ident: 10223_CR77 publication-title: Hepatology doi: 10.1002/hep.26376 – volume: 16 start-page: 695 issue: 6 year: 2019 ident: 10223_CR75 publication-title: Hepatol Int doi: 10.1007/s12072-019-09992-x – volume: 39 start-page: 614 year: 2003 ident: 10223_CR122 publication-title: J Hepatol doi: 10.1016/S0168-8278(03)00394-5 – volume: 68 start-page: 1476 year: 2018 ident: 10223_CR30 publication-title: Hepatology doi: 10.1002/hep.29922 – volume: 6 start-page: 531 year: 2012 ident: 10223_CR12 publication-title: Hepatol Int doi: 10.1007/s12072-012-9365-4 – volume: 26 start-page: 936 year: 2019 ident: 10223_CR118 publication-title: J Viral Hepat doi: 10.1111/jvh.13091 – volume: 18 start-page: 457 year: 2020 ident: 10223_CR27 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2019.07.010 – volume: 58 start-page: 98 year: 2013 ident: 10223_CR71 publication-title: Hepatology doi: 10.1002/hep.26180 – volume: 26 start-page: 1146 year: 2019 ident: 10223_CR87 publication-title: J Viral Hepat doi: 10.1111/jvh.13126 – volume: 13 start-page: 260 year: 2019 ident: 10223_CR62 publication-title: Hepatol Int doi: 10.1007/s12072-019-09943-6 – volume: 147 start-page: 75 year: 2017 ident: 10223_CR89 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2017.10.003 – volume: 19 start-page: 561 year: 2018 ident: 10223_CR125 publication-title: J Dig Dis doi: 10.1111/1751-2980.12654 – volume: 14 start-page: 1490 year: 2016 ident: 10223_CR106 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2016.03.024 – volume: 45 start-page: 75 year: 2010 ident: 10223_CR40 publication-title: Scand J Gastroenterol doi: 10.3109/00365520903394550 – volume: 69 start-page: 584 year: 2018 ident: 10223_CR55 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.05.004 – volume: 70 start-page: 1045 year: 2019 ident: 10223_CR86 publication-title: Hepatology doi: 10.1002/hep.30474 – volume: 58 start-page: 1888 year: 2013 ident: 10223_CR101 publication-title: Hepatology doi: 10.1002/hep.26549 – volume: 2 start-page: 1160 year: 2018 ident: 10223_CR21 publication-title: Hepatol Commun doi: 10.1002/hep4.1247 – volume: 143 start-page: 629 year: 2012 ident: 10223_CR47 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.05.039 – volume-title: Global hepatitis report, 2017 year: 2017 ident: 10223_CR1 – volume: 18 start-page: 2989 year: 2020 ident: 10223_CR105 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.04.048 – volume: 154 start-page: 2280 year: 2018 ident: 10223_CR109 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.03.066 – volume: 139 start-page: 491 year: 2010 ident: 10223_CR78 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.03.059 – volume: 17 start-page: 182 year: 2019 ident: 10223_CR113 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.05.047 – volume: 72 start-page: 19A year: 2020 ident: 10223_CR50 publication-title: Hepatology doi: 10.1002/hep.31008 – volume: 13 start-page: 1984 year: 2015 ident: 10223_CR85 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.06.002 – ident: 10223_CR95 – volume: 8 start-page: e125 year: 2017 ident: 10223_CR130 publication-title: Clin Transl Gastroenterol doi: 10.1038/ctg.2017.51 – volume: 17 start-page: 298 year: 2010 ident: 10223_CR123 publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2009.01178.x – volume: 30 start-page: 567 year: 1999 ident: 10223_CR13 publication-title: Hepatology doi: 10.1002/hep.510300221 – volume: 67 start-page: 773 year: 2018 ident: 10223_CR2 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6728a2 – volume: 68 start-page: 425 year: 2018 ident: 10223_CR7 publication-title: Hepatology doi: 10.1002/hep.29640 – volume: 49 start-page: 107 year: 2019 ident: 10223_CR110 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.15058 – volume: 6 start-page: 735 year: 2012 ident: 10223_CR74 publication-title: Hepatol Int doi: 10.1007/s12072-012-9344-9 – volume: 65 start-page: 700 year: 2016 ident: 10223_CR114 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.05.029 – volume: 61 start-page: 777 year: 2014 ident: 10223_CR91 publication-title: J Hepatol doi: 10.1016/j.jhep.2014.05.044 – volume: 58 start-page: 1537 year: 2013 ident: 10223_CR72 publication-title: Hepatology doi: 10.1002/hep.26301 – volume: 41 start-page: 867 year: 2015 ident: 10223_CR83 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13150 – volume: 21 start-page: 337 year: 2016 ident: 10223_CR92 publication-title: Antivir Ther doi: 10.3851/IMP3019 – volume: 52 start-page: 886 year: 2010 ident: 10223_CR68 publication-title: Hepatology doi: 10.1002/hep.23785 – volume: 5 start-page: 167 year: 2020 ident: 10223_CR32 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(19)30342-5 – volume: 71 start-page: 35 year: 2019 ident: 10223_CR65 publication-title: J Hepatol doi: 10.1016/j.jhep.2019.02.021 – volume: 24 start-page: 599 year: 2017 ident: 10223_CR37 publication-title: J Viral Hepat doi: 10.1111/jvh.12683 – volume: 66 start-page: 275 year: 2017 ident: 10223_CR76 publication-title: J Hepatol doi: 10.1016/j.jhep.2016.08.022 – year: 2021 ident: 10223_CR128 publication-title: Int J Infect Dis doi: 10.1093/cid/ciab007 – volume: 351 start-page: 1521 year: 2004 ident: 10223_CR70 publication-title: N Engl J Med doi: 10.1056/NEJMoa033364 – volume: 57 start-page: 508 year: 2012 ident: 10223_CR60 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.04.037 – volume: 58 start-page: 676 year: 2013 ident: 10223_CR42 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.11.039 – volume: 67 start-page: 918 year: 2017 ident: 10223_CR48 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.07.012 – volume: 64 start-page: 667 year: 2015 ident: 10223_CR80 publication-title: Gut doi: 10.1136/gutjnl-2014-307237 – volume: 381 start-page: 468 year: 2013 ident: 10223_CR69 publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 – volume: 359 start-page: 2442 year: 2008 ident: 10223_CR63 publication-title: N Engl J Med doi: 10.1056/NEJMoa0802878 – volume: 128 start-page: 668 year: 2018 ident: 10223_CR57 publication-title: J Clin Investig doi: 10.1172/JCI92812 – volume: 2 start-page: 177 year: 2017 ident: 10223_CR97 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30189-3 – volume: 49 start-page: 218 year: 2019 ident: 10223_CR82 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.15053 – volume: 38 start-page: 90 issue: Suppl 1 year: 2018 ident: 10223_CR131 publication-title: Liver Int doi: 10.1111/liv.13654 – volume: 73 start-page: 843 issue: 2 year: 2021 ident: 10223_CR59 publication-title: Hepatology doi: 10.1002/hep.31525 – volume: 27 start-page: 1167 year: 2012 ident: 10223_CR29 publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2011.07047.x – volume: 47 start-page: 1170 year: 2018 ident: 10223_CR79 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14560 – volume: 14 start-page: 1813 year: 2016 ident: 10223_CR84 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2016.07.002 – volume: 13 start-page: 665 year: 2019 ident: 10223_CR33 publication-title: Hepatol Int doi: 10.1007/s12072-019-09989-6 – volume: 20 start-page: O687 year: 2014 ident: 10223_CR126 publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12605 – volume: 24 start-page: 997 year: 2018 ident: 10223_CR104 publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2017.12.013 – volume: 68 start-page: 415 year: 2018 ident: 10223_CR34 publication-title: Hepatology doi: 10.1002/hep.29497 – volume: 74 start-page: 1064 issue: 5 year: 2021 ident: 10223_CR56 publication-title: J Hepatol doi: 10.1016/j.jhep.2020.11.043 – volume: 43 start-page: 134 year: 2016 ident: 10223_CR38 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13440 – volume: 43 start-page: 43 year: 2016 ident: 10223_CR127 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2015.10.019 – volume: 8 start-page: 64 year: 2014 ident: 10223_CR73 publication-title: Hepatol Int doi: 10.1007/s12072-013-9485-5 – volume: 11 start-page: 398 year: 2011 ident: 10223_CR14 publication-title: BMC Cancer doi: 10.1186/1471-2407-11-398 – volume: 42 start-page: 243 year: 2015 ident: 10223_CR39 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13272 – volume: 27 start-page: 118 year: 2020 ident: 10223_CR108 publication-title: J Viral Hepat doi: 10.1111/jvh.13211 – volume: 14 start-page: 317 year: 2020 ident: 10223_CR51 publication-title: Hepatol Int doi: 10.1007/s12072-019-09991-y – volume: 143 start-page: 963 year: 2012 ident: 10223_CR53 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.07.014 – volume: 18 start-page: 2803 year: 2020 ident: 10223_CR102 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.04.037 – volume: 216 start-page: S750 year: 2017 ident: 10223_CR98 publication-title: J Infect Dis doi: 10.1093/infdis/jix382 – volume: 60 start-page: 62 year: 2014 ident: 10223_CR43 publication-title: J Hepatol doi: 10.1016/j.jhep.2013.08.023 – volume: 70 start-page: 361 year: 2019 ident: 10223_CR5 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.10.014 – volume: 53 start-page: 1854 year: 2011 ident: 10223_CR19 publication-title: Hepatology doi: 10.1002/hep.24318 – volume: 217 start-page: 1656 year: 2018 ident: 10223_CR58 publication-title: J Infect Dis doi: 10.1093/infdis/jiy097 – volume: 68 start-page: 2206 year: 2019 ident: 10223_CR81 publication-title: Gut doi: 10.1136/gutjnl-2019-318981 – volume: 63 start-page: 1481 year: 2016 ident: 10223_CR35 publication-title: Hepatology doi: 10.1002/hep.28438 – volume: 16 start-page: 1249 year: 2011 ident: 10223_CR46 publication-title: Antivir Ther doi: 10.3851/IMP1921 – volume: 26 start-page: 697 year: 2019 ident: 10223_CR116 publication-title: J Viral Hepat doi: 10.1111/jvh.13068 – year: 2020 ident: 10223_CR119 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.12.005 – volume: 23 start-page: 677 year: 2018 ident: 10223_CR129 publication-title: Antivir Ther doi: 10.3851/IMP3256 |
| SSID | ssj0055616 |
| Score | 2.4970975 |
| Snippet | Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with potent and safe nucleos(t)ide analogs (NAs) can reduce... |
| SourceID | proquest crossref springer |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 833 |
| SubjectTerms | Alanine Alanine transaminase Antiviral drugs Biomarkers Chronic infection Cirrhosis Colorectal Surgery Complications Deoxyribonucleic acid DNA Fibrosis Guidelines Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B surface antigen Hepatocellular carcinoma Hepatology Immune system Interferon Liver cancer Liver cirrhosis Medicine Medicine & Public Health Patients Risk groups Strategy Surgery Therapy Viruses |
| Title | APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients |
| URI | https://link.springer.com/article/10.1007/s12072-021-10223-5 https://www.proquest.com/docview/2563791613 https://www.proquest.com/docview/2555112797 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZS8QwEB7UBfFFPHF1XSL4oGigSZqmfazigReiLqxPpTmqC9IV2_3_Jj12UVTwudNpmZlmvnRmvgDsK0_oKA0oDkyosK8JwaFPJKZaeDbb8kxmbhr59i64HPhXQz5shsKKttu9LUlWK_Vs2I16gmLXUuB2KQzzeehwxydlo3hA43b9dec9BnUt2e6VLZppRmV-1vE1Hc0w5reyaJVtzldguYGJKK79ugpzJl-DxdumEL4OD_F9_HiDXiYj7dyGxjlyFAFu-AnljqJ4XByUhyNtUJrXv2cKNMqRqqlw0atxjdTlqEAnqGFWLTZgcH72dHqJm-MRsLKoqcSKKGaYF2bUMBJ4qbQJyRjuW6tnWhnlB1JIqaiimSdJEPFIKpWlVEkaRCIK2SYs5OPcbAEKta_9lBGS2mytlQyVFDy1uoy08JH5XSCtlRLVcIe7IyzekhnrsbNsYi2bVJZNeBeOpve818wZf0r3WuMnzVdUJBaOMWFfgLAu7E0v2_h3RY00N-OJk-EOM4pIdOG4ddpMxe9P3P6f-A4sURc3Ve9fDxbKj4nZtXiklH3oxBfP12d9mL8Ykn4VjJ_W0dcu |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS-wwEB50BfVF1KO4XiP4cEQDTdI27eMqyqq7cji64FtpLtUF6Yrt_n8zvbgoKvjcNC3fTDNfOjNfAI60J02chpyGNtLUN4zRyGeKciM9F22DTGXYjTy8Dfsj__oheGiawoq22r1NSVYr9azZjXuSUywpwF2KoME8LGCaEbdcI95r11887zGsc8lur-zYTNMq8_UcH8PRjGN-SotW0eZyFVYamkh6tV3XYM7m67A4bBLhf-B_71_vbkAep2ODZiOTnKBEADY_kRwliifF3_J4bCxJ8_r3TEHGOdG1FC55slhIXY4LckYaZdViA0aXF_fnfdocj0C1Y00l1UwLK7wo41aw0EuVC0jWBr5DPTPaaj9UUinNNc88xcI4iJXWWcq14mEs40hsQief5HYLSGR846eCsdRFa6NVpJUMUjeXVY4-Cr8LrEUp0Y12OB5h8ZzMVI8R2cQhm1TIJkEXTt7veamVM34cvduCnzRfUZE4OiakewEmunD4ftn5PyY10txOpjgmQM4oY9mF09Zosym-f-L274YfwFL_fjhIBle3NzuwzNGHqjrAXeiUr1O757hJqfYrV3wDKZjXjA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZT9tAEB61qYT6gqCHGgiwSH1o1a7wHvbaj-GIoIUoahuJN8t7GCKhDcLO_2fHB2mrtlKfPR5bM7uebz0z3wC8N5GyWZFwmrjUUGkZo6lkmnKrohBt41KX2I18NU3O5_LLdXz9Uxd_U-3epyTbngZkafL10b0tj9aNbzxSnGJ5AZ5YBI2fwwsZYjUWdc35uP8W4-zHpM0rh3NzQDZd28yfdfwamtZ487cUaRN5Jluw2UFGMm59vA3PnH8FG1ddUvw1fBvPxt8vyc1qYdGFZOkJ0gVgIxTxSFe8rD7UHxfWkcK3v2oqsvDEtLS45NZhUXW9qMgx6VhWqzcwn5z9ODmn3agEagKCqqlhRjgRpSV3giVRoUNwci6WwQOlNc7IRCutDTe8jDRLsjjTxpQFN5onmcpS8RYGfundOyCplVYWgrEiRG5rdGq0iougy-kAJYUcAuutlJuORxzHWdzlawZktGweLJs3ls3jIXx6uue-ZdH4p_SoN37e7agqD9BMqPACTAzh8Oly2AuY4Ci8W65QJkb8qDI1hM-909Yq_v7Enf8TP4CN2ekkv7yYft2FlxyXUFMSOIJB_bByewGm1Hq_WYmP9B7b0Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=APASL+guidance+on+stopping+nucleos%28t%29ide+analogues+in+chronic+hepatitis+B+patients&rft.jtitle=Hepatology+international&rft.au=Kao%2C+Jia-Horng&rft.au=Jeng%2C+Wen-Juei&rft.au=Ning%2C+Qin&rft.au=Su%2C+Tung-Hung&rft.date=2021-08-01&rft.issn=1936-0541&rft.eissn=1936-0541&rft.volume=15&rft.issue=4&rft.spage=833&rft_id=info:doi/10.1007%2Fs12072-021-10223-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-0533&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-0533&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-0533&client=summon |